25 LLC’s NovoCure NVCR Stock Holding History

25 LLC’s Portfolio NVCR Stock Details NVCR Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q3	–	Sell	-52	Closed	-$2.08K	–	376
2023 Q2	$2.08K	Hold	52	–	–	﹤0.01%	211
2023 Q1	$3.61K	Buy	+52	New	+$4.16K	﹤0.01%	186

Other funds holding NVCR

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return

Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Baillie Gifford & Co Edinburgh, United Kingdom $97.9B AUM 20.73% 1-Year Est. Return

DTC

Deep Track Capital Greenwich, Connecticut $6.12B AUM 144% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Voloridge Investment Management Jupiter, Florida $25B AUM 28.08% 1-Year Est. Return

25 LLC's NVCR Position: Q3 2023 in Review

25 LLC sold out of NovoCure (NVCR) in Q3 2023, closing a stake of 52 shares — an estimated $2.08K sold.

25 LLC first reported a position in NVCR in Q1 2023 and held it in 2 quarters. The position peaked at $3.61K in Q1 2023. 226 funds tracked by Wall St. Rank hold NVCR as of Q3 2023.

25 LLC reported no remaining NovoCure position as of Q3 2023 after selling out during the quarter.
25 LLC sold 52 NovoCure shares in Q3 2023, an estimated $2.08K.
25 LLC first reported a position in NovoCure in Q1 2023 and held it in 2 quarters.
25 LLC's NovoCure position peaked at $3.61K in Q1 2023.
226 funds tracked by Wall St. Rank held NovoCure as of Q3 2023.

Based on 25 LLC's 13F filing for Q3 2023, filed 18 Oct 2023.